Navigation Links
VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
Date:5/15/2008

of the date they are made, and VIA undertakes no obligation to update publicly any of these statements in light of new information or future events.


'/>"/>
SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014   Surefire Medical ... infusion systems designed to maximize targeted delivery of embolization ... to announce that oncologist John R. Daniels , ... Cancer Center, and surgical oncologist Steven C. Katz ... joined the Company,s Scientific Advisory Board (SAB).    ...
(Date:10/22/2014)... AUSTIN, Texas , Oct. 22, ... today announced they have entered into a license ... designed to target cancers. PhosImmune possesses ... on the surfaces of tumor cells in association ... derived from proteins that play a role in ...
(Date:10/22/2014)... LA JOLLA, Calif. , Oct. 22, ... RGLS ), a biopharmaceutical company leading ... targeting microRNAs, today announced that it has ... from an ongoing clinical study evaluating RG-101, ... for the treatment of hepatitis C virus ...
Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
(Date:10/22/2014)... October 22, 2014 Although there are only 24 ... for many people who have trouble finding time within their busy ... exercise for long periods of time to get in shape. Here ... while on the go. , Change Up Your Commute , ... work to add some exercise into your daily routine. If you ...
(Date:10/22/2014)... Steven Reinberg HealthDay Reporter ... quickly add weight and length may be showing a genetic ... In adults, certain genes have been linked to increased body ... in fat and lean muscle, the researchers said. At ... taller. By ages 2 and 3, however, these genes were ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... part of conventional in vitro fertilization (IVF) -- the incubation ... place in a device inside the vagina, new research suggests. ... the device, called an INVOcell, might sharply cut costs for ... the technology more accessible to those who don,t live near ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 The newly ... must-have source of thousands of facts, figures and forecasts ... and 68 medical sector forecast categories the Worldwide ... global, regional and national views on the worldwide medical ... , The report gives you data for 2010-2019, covering ...
(Date:10/20/2014)... October 20, 2014 ASCNYC (ascnyc.org) ... that helps New Yorkers living with HIV/AIDS and ... health, housing, recovery and self-sufficiency. Each year, ASCNYC ... local community through their tireless efforts. , ... Shapses , has been selected as this year’s ...
Breaking Medicine News(10 mins):Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... can worsen the impact of asthma and may also mask ... Zealand, who studied lung function in asthmatic women with a ... first prospective study to reveal a significant comparative difference in ... attack in obese and non-obese individuals. , The research ...
... Trust, Inc.,(NYSE: BMR ), a real estate investment trust focused ... results for,the first quarter ended March 31, 2008., Highlights:, ... million, or $0.46 per diluted share, ... share, equivalent to an annualized common stock ...
... Brookdale Senior,Living Inc. (NYSE: BKD ) announced ... financial results after the market closes on Wednesday, May ... discuss the results on,Thursday, May 8, 2008 at 8:00 ... (866) 845-7252 (from within the U.S.) or (706) 634-9069 ...
... 30 New data is showing a dramatic,reduction ... in this country.,Here,s more on one group,s 20-year ... to this report from Safe Kids Worldwide at:, ... audio, text, graphics and,photos for free and unrestricted ...
... eligible Medicaid members, PHOENIX, April 30 ... law, allowing the state Medicaid program to,expend moneys ... Introduced by Sen. Barbara Leff (R-Paradise Valley), ... state,s General Fund and will provide benefits,for nicotine ...
... in relapsing remitting illness , , WEDNESDAY, April 30 (HealthDay ... people with the relapsing remitting form of multiple sclerosis ... the disease were randomly selected to receive either 20 ... for 24 weeks. MRI brain scans were conducted every ...
Cached Medicine News:Health News:Obesity worsens impact of asthma 2Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 2Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 3Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 4Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 5Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 6Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 7Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 8Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 9Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 10Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 11Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 12Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 13Health News:Brookdale Announces First Quarter 2008 Release and Earnings Call 2Health News:Governor Napolitano Signs Smoking Cessation Bill 2Health News:Prozac Reduces Disease Activity in MS Patients 2
Fine abrasive for knife sharpening, 6 grams net...
Knife sharpening back for Standard Knife, C Profile...
Standard knife with box, C profile...
... stage is a refrigerated design for use as ... use with the 8000 sledge microtome, however, it ... refrigerated stage gives a large working area of ... to provide good adhesion between the specimen and ...
Medicine Products: